Patient no. | Sex | Age (y) | BMI | Histology | Prior treatments | Histology and MIBG scan | Tumor sites | Activity (MBq) | Tumor detection |
---|---|---|---|---|---|---|---|---|---|
1 | M | 23 | 21 | Neuroblastoma | S, chemo, RT | G3, MIBG neg | Bone, hep, lym | 82.3 | Pos |
2 | M | 32 | 23 | Pheochromocytoma | S, chemo, RT, PRRT | Chromogranine pos | Bone, hep, pul | 89.7 | Pos |
3 | F | 50 | 21 | Neuroendocrine tumor | Chemo, RT | Chromogranine pos | Bone, hep, lym, pul | 87.2 | Pos |
4 | M | 7 | 13 | Neuroblastoma | S, chemo, RT, ABMT | MIBG neg, VMA/HVA neg, MYCN pos | Bone | 50.8 | Pos |
5 | F | 8 | 16 | Neuroblastoma | S, chemo, RT, ABMT | MIBG, NSE, VMA, MYCN neg | Bone, BM | 32.6 | Pos |
6 | M | 8 | 16 | Neuroblastoma | S, chemo, RT, ABMT | MYCN neg, no chromosome aberration 1 (p36) | Bone | 27 | Pos |
7* | M | 7 | 14 | Neuroblastoma | S, chemo, RT, ABMT, GD2 | MYCN neg, MIBG pos | Bone, BM | 24.7 | Neg |
8* | M | 4 | 16 | Neuroblastoma | S, chemo, MIBG-T, ABMT | MYCN neg, imbalance chromosome 1 (p36) | Bone, BM | 21.2 | Neg |
9 | F | 4 | 13 | Neuroblastoma | S, chemo, RT, ABMT | MIBG neg | Bone, lym | 22.3 | Pos |
10 | F | 13 | 15 | Neuroblastoma | S, chemo, MIBG-T, ABMT, GD2 | MYCN neg, 1 p-deletion pos, catecholamine pos, MIBG pos | Bone, BM | 46.8 | Pos |
11 | M | 51 | 29 | Ewing sarcina | S, chemo, RT, ABMT | Ewing sarcoma | Cerebral, pul | 83.2 | Neg |
12 | F | 20 | 19 | Ewing sarcina | S, chemo, RT, ABMT | Ewing sarcoma | Hep, pul | 59 | Neg |
13 | M | 18 | 30 | Ewing sarcina | S, chemo | Ewing sarcoma | Pul | 130.8 | Neg |
14 | M | 13 | 25 | Ewing sarcina | S, chemo, RT, ABMT | Ewing sarcoma | Bone, pul | 76.5 | Pos |
15 | M | 17 | 18 | Ewing sarcina | S, chemo, ABMT | Ewing sarcoma | Bone, lym | 80.5 | Pos |
16 | F | 18 | 27 | Ewing sarcina | S, chemo, RT, ABMT | Ewing sarcoma | Bone | 79.5 | Pos |
17 | M | 19 | 19 | Osteosarcoma | S, chemo | Osteosarcoma | Bone, lym, pul, soft | 82.1 | Pos |
18 | M | 11 | 19 | Osteosarcoma | S, GD2 | Osteosarcoma | No metastasis | 84 | Pos |
19 | M | 22 | 17 | Osteosarcoma | S, chemo | Osteosarcoma | GI, pul | 105 | Neg |
20* | M | 5 | 17 | Neuroblastoma | S, chemo, RT, ABMT | MYCN and MIBG neg, no chromosome aberration 1 (p36) | Bone, BM, lym | 59.3 | Neg |
*Not suitable for dosimetric analysis.
BMI = body mass index; MIBG-T = 131I-MIBG therapy; S = surgery; chemo = chemotherapy; RT = focal radiotherapy; neg = negative; bone = skeletal metastases; hep = hepatic metastases; lym = lymph node metastases; pos = positive; PRRT = peptide receptor radiotherapy; pul = pulmonary metastases; ABMT = myeloablative chemotherapy with stem-cell rescue; VMA = vanillylmandelic acid; HVA = homovanillic acid; MYCN = N-myc proto-oncogene protein; NSE = neuron-specific enolase; BM = bone marrow metastases; GD2 = nonradioactive GD2-antibody therapy; soft = soft-tissue metastases; GI = gastrointestinal tract metastases.